Table II.
Median timing between study samples collection and triage questionnaires or nasopharyngeal SARS-CoV-2 test in each group defined according to the results of SARS-CoV-2 risk evaluation.
| Results of SARS- CoV-2 risk evaluation | Median timing (days) (min–max) | |
|---|---|---|
| Group 1 | Questionnaire/−/or UK | 1 (0–13) |
| SARS-CoV-2 test/−/ | 5 (0–13) | |
| Group 2 | Questionnaire/+/ | 1 (0–7) |
| SARS-CoV-2 test/−/ | 7 (2–12) | |
| Group 3 | Questionnaire/+/or/−/ | 0 (0–11) |
| (1 questionnaire UK) | ||
| SARS-CoV-2 test/+/ | 4 (0–7) | |
| Group 4 | Questionnaire/+/or/−/ | 1 (0–10) |
| (5 questionnaires UK) | ||
| SARS-CoV-2 test UK | NA |
NA, not applicable; UK, unknown.